Kalytera Therapeutics Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Kalytera Therapeutics is a clinical-stage biotechnology company focused on developing cannabidiol (CBD) and next-generation cannabinoid therapies for serious human diseases, with an initial focus on graft versus host disease (GVHD). Its lead program evaluates CBD for the prevention and treatment of GVHD, with a late-stage clinical testing trajectory that includes an ongoing Phase 2 study in GVHD prevention and plans to launch a seamless Phase 2-3 pivotal trial for treatment of acute GVHD later this year. The company holds two U.S. patents covering CBD use in GVHD prevention and treatment and has four orphan drug designations for GVHD in the United States and Europe. In addition to GVHD, Kalytera has initiated a preclinical program to develop a novel cannabinoid compound for the treatment of acute and chronic pain. The firm is headquartered in San Rafael, California, operates in the biotechnology research industry, employs between 11 and 50 people, and is listed on the TSXV under the ticker KALY.